640 related articles for article (PubMed ID: 32448716)
1. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
2. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
[TBL] [Abstract][Full Text] [Related]
3. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
[TBL] [Abstract][Full Text] [Related]
4. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
Giugliano D; Scappaticcio L; Longo M; Caruso P; Maiorino MI; Bellastella G; Ceriello A; Chiodini P; Esposito K
Cardiovasc Diabetol; 2021 Sep; 20(1):189. PubMed ID: 34526024
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.
Monami M; Nreu B; Scatena A; Giannini S; Andreozzi F; Sesti G; Mannucci E
J Endocrinol Invest; 2017 Nov; 40(11):1251-1258. PubMed ID: 28569363
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract][Full Text] [Related]
9. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
Mannucci E; Dicembrini I; Nreu B; Monami M
Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
12. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
14. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
[TBL] [Abstract][Full Text] [Related]
15. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
Peterson SC; Barry AR
Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
20. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
Minerva Endocrinol (Torino); 2023 Jun; 48(2):206-213. PubMed ID: 32720500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
